Abstract
The authors describe an HIV-infected patient with moderate renal failure receiving combination antiretroviral therapy. Because of dyslipidaemia he was initially treated with pravastatin but developed rhabdomyolysis after a switch to rosuvastatin. With this case we illustrate that statins as well as antiretroviral therapy are susceptible to clinical relevant drug-drug or drug-disease interactions. Knowledge of these interactions is important to provide patients with the best possible care.
MeSH terms
-
Anti-HIV Agents / adverse effects*
-
Anti-HIV Agents / therapeutic use
-
Drug Therapy, Combination
-
Dyslipidemias / chemically induced
-
Dyslipidemias / drug therapy
-
Fluorobenzenes / adverse effects*
-
Fluorobenzenes / therapeutic use
-
HIV Infections / complications
-
HIV Infections / drug therapy*
-
HIV Infections / virology
-
HIV-1 / drug effects
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
-
Lopinavir
-
Male
-
Middle Aged
-
Pyrimidines / adverse effects*
-
Pyrimidines / therapeutic use
-
Pyrimidinones / adverse effects*
-
Pyrimidinones / therapeutic use
-
Renal Insufficiency / complications*
-
Renal Insufficiency / drug therapy
-
Rhabdomyolysis / chemically induced
-
Rhabdomyolysis / drug therapy*
-
Ritonavir / adverse effects*
-
Ritonavir / therapeutic use
-
Rosuvastatin Calcium
-
Sulfonamides / adverse effects*
-
Sulfonamides / therapeutic use
-
Treatment Outcome
Substances
-
Anti-HIV Agents
-
Fluorobenzenes
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Pyrimidines
-
Pyrimidinones
-
Sulfonamides
-
Lopinavir
-
Rosuvastatin Calcium
-
Ritonavir